SinuGeniX is an emerging medical device company focused on commercializing a product family, with initial focus on its patented RegENT™ System, the next generation of balloon dilation sinuplasty (BDS) for the treatment of chronic rhinosinusitis (CRS), which affects approximately 35 million people annually in the U.S.
A 2015 article in the Journal of Allergy and Clinical Immunology based on a U.S. MEPS (Medical Expenditure Panel Survey) survey found that CRS represents 5% of the annual U.S. Healthcare Budget, resulting in an overall expenditure of $60.2 to 64.5 billion USD for treatment.